BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

169 related articles for article (PubMed ID: 24910416)

  • 1. Significant survival impact of MACC1 polymorphisms in HER2 positive breast cancer patients.
    Muendlein A; Hubalek M; Geller-Rhomberg S; Gasser K; Winder T; Drexel H; Decker T; Mueller-Holzner E; Chamson M; Marth C; Lang AH
    Eur J Cancer; 2014 Aug; 50(12):2134-41. PubMed ID: 24910416
    [TBL] [Abstract][Full Text] [Related]  

  • 2. A common variant of the MACC1 gene is significantly associated with overall survival in colorectal cancer patients.
    Lang AH; Geller-Rhomberg S; Winder T; Stark N; Gasser K; Hartmann B; Kohler B; Grizelj I; Drexel H; Muendlein A
    BMC Cancer; 2012 Jan; 12():20. PubMed ID: 22251819
    [TBL] [Abstract][Full Text] [Related]  

  • 3. A genetic variant in p63 (rs17506395) is associated with breast cancer susceptibility and prognosis.
    Zhang N; Huo Q; Wang X; Chen X; Long L; Guan X; Jiang L; Ma T; Hu W; Yang Q
    Gene; 2014 Feb; 535(2):170-6. PubMed ID: 24316488
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Single nucleotide polymorphisms in the metastasis-associated in colon cancer-1 gene predict the recurrence of hepatocellular carcinoma after transplantation.
    Zheng Z; Gao S; Yang Z; Xie H; Zhang C; Lin B; Wu L; Zheng S; Zhou L
    Int J Med Sci; 2014; 11(2):142-50. PubMed ID: 24465159
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Genetic Variation in Metastasis-Associated in Colon Cancer-1 and the Risk of Breast Cancer Among the Chinese Han Population: A STROBE-Compliant Observational Study.
    Dai ZJ; Liu XH; Kang HF; Wang XJ; Jin TB; Zhang SQ; Feng T; Ma XB; Wang M; Feng YJ; Liu K; Xu P; Guan HT
    Medicine (Baltimore); 2016 Feb; 95(6):e2801. PubMed ID: 26871844
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Association of a common genetic variant of the IGF-1 gene with event-free survival in patients with HER2-positive breast cancer.
    Muendlein A; Lang AH; Geller-Rhomberg S; Winder T; Gasser K; Drexel H; Decker T; Mueller-Holzner E; Chamson M; Marth C; Hubalek M
    J Cancer Res Clin Oncol; 2013 Mar; 139(3):491-8. PubMed ID: 23180020
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Prognosis of metastatic breast cancer subtypes: the hormone receptor/HER2-positive subtype is associated with the most favorable outcome.
    Lobbezoo DJ; van Kampen RJ; Voogd AC; Dercksen MW; van den Berkmortel F; Smilde TJ; van de Wouw AJ; Peters FP; van Riel JM; Peters NA; de Boer M; Borm GF; Tjan-Heijnen VC
    Breast Cancer Res Treat; 2013 Oct; 141(3):507-14. PubMed ID: 24104881
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Prognostic impact of VEGFA germline polymorphisms in patients with HER2-positive primary breast cancer.
    Maae E; Andersen RF; Steffensen KD; Jakobsen EH; Brandslund I; Sørensen FB; Jakobsen A
    Anticancer Res; 2012 Sep; 32(9):3619-27. PubMed ID: 22993299
    [TBL] [Abstract][Full Text] [Related]  

  • 9. A common and functional gene variant in the vascular endothelial growth factor a predicts clinical outcome in early-stage breast cancer.
    Absenger G; Szkandera J; Stotz M; Pichler M; Winder T; Langsenlehner T; Langsenlehner U; Samonigg H; Renner W; Gerger A
    Mol Carcinog; 2013 Nov; 52 Suppl 1():E96-102. PubMed ID: 23625573
    [TBL] [Abstract][Full Text] [Related]  

  • 10. SNPs in the coding region of the metastasis-inducing gene MACC1 and clinical outcome in colorectal cancer.
    Schmid F; Burock S; Klockmeier K; Schlag PM; Stein U
    Mol Cancer; 2012 Jul; 11():49. PubMed ID: 22838389
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Metastasis-associated in colon cancer 1 is an independent prognostic biomarker for survival in Klatskin tumor patients.
    Lederer A; Herrmann P; Seehofer D; Dietel M; Pratschke J; Schlag P; Stein U
    Hepatology; 2015 Sep; 62(3):841-50. PubMed ID: 25953673
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Differential role of MACC1 expression and its regulation of the HGF/c‑Met pathway between breast and colorectal cancer.
    Sueta A; Yamamoto Y; Yamamoto-Ibusuki M; Hayashi M; Takeshita T; Yamamoto S; Omoto Y; Iwase H
    Int J Oncol; 2015 May; 46(5):2143-53. PubMed ID: 25738887
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Lapatinib combined with letrozole versus letrozole and placebo as first-line therapy for postmenopausal hormone receptor-positive metastatic breast cancer.
    Johnston S; Pippen J; Pivot X; Lichinitser M; Sadeghi S; Dieras V; Gomez HL; Romieu G; Manikhas A; Kennedy MJ; Press MF; Maltzman J; Florance A; O'Rourke L; Oliva C; Stein S; Pegram M
    J Clin Oncol; 2009 Nov; 27(33):5538-46. PubMed ID: 19786658
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Interleukin-6 -174G-->C polymorphism is associated with improved outcome in high-risk breast cancer.
    DeMichele A; Martin AM; Mick R; Gor P; Wray L; Klein-Cabral M; Athanasiadis G; Colligan T; Stadtmauer E; Weber B
    Cancer Res; 2003 Nov; 63(22):8051-6. PubMed ID: 14633738
    [TBL] [Abstract][Full Text] [Related]  

  • 15. FGFR4 Arg388 allele is associated with resistance to adjuvant therapy in primary breast cancer.
    Thussbas C; Nahrig J; Streit S; Bange J; Kriner M; Kates R; Ulm K; Kiechle M; Hoefler H; Ullrich A; Harbeck N
    J Clin Oncol; 2006 Aug; 24(23):3747-55. PubMed ID: 16822847
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Impact of FOXA1 expression on the prognosis of patients with hormone receptor-positive breast cancer.
    Hisamatsu Y; Tokunaga E; Yamashita N; Akiyoshi S; Okada S; Nakashima Y; Aishima S; Morita M; Kakeji Y; Maehara Y
    Ann Surg Oncol; 2012 Apr; 19(4):1145-52. PubMed ID: 21984487
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Expression of matrix metalloproteinase (MMP)-2 and MMP-9 in breast cancer with a special reference to activator protein-2, HER2, and prognosis.
    Pellikainen JM; Ropponen KM; Kataja VV; Kellokoski JK; Eskelinen MJ; Kosma VM
    Clin Cancer Res; 2004 Nov; 10(22):7621-8. PubMed ID: 15569994
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Improved outcome of high-risk early HER2 positive breast cancer with high CXCL13-CXCR5 messenger RNA expression.
    Razis E; Kalogeras KT; Kotoula V; Eleftheraki AG; Nikitas N; Kronenwett R; Timotheadou E; Christodoulou C; Pectasides D; Gogas H; Wirtz RM; Makatsoris T; Bafaloukos D; Aravantinos G; Televantou D; Pavlidis N; Fountzilas G
    Clin Breast Cancer; 2012 Jun; 12(3):183-93. PubMed ID: 22607768
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Expression of HER2 and its association with AP-2 in breast cancer.
    Pellikainen J; Naukkarinen A; Ropponen K; Rummukainen J; Kataja V; Kellokoski J; Eskelinen M; Kosma VM
    Eur J Cancer; 2004 Jul; 40(10):1485-95. PubMed ID: 15196531
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The impact of renin-angiotensin system, angiotensin І converting enzyme (insertion/deletion), and angiotensin ІІ type 1 receptor (A1166C) polymorphisms on breast cancer survival in Iran.
    Namazi S; Daneshian A; Mohammadianpanah M; Jafari P; Ardeshir-Rouhani-Fard S; Nasirabadi S
    Gene; 2013 Dec; 532(1):125-31. PubMed ID: 24055489
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.